Medical Mutual

Does Medical Mutual cover Wegovy?

Quick answer · Weight Loss

Medical Mutual covers it only when the plan's benefit includes it on Employer / Commercial Insurance.

  • Employer / Commercial Insurance: Depends on your plan's benefit. Prior Authorization is only available for members with plan benefit coverage of weight loss drugs. Medications for the treatment of weight loss are specifically excluded as a covered benefit for many plans.

Last verified June 10, 2026. Source: Weight-Loss-GlucagonLike-Peptide1-GLP1-Agonists.pdf. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What Medical Mutual requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Prior Authorization is only available for members with plan benefit coverage of weight loss drugs. Medications for the treatment of weight loss are specifically excluded as a covered benefit for many plans.

What you need to qualify

  • Age 12 and older
  • BMI of 32 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, knee osteoarthritis, asthma, COPD, NASH/NAFLD, PCOS, and CAD)
  • BMI at or above the 95th percentile for age and sex
  • 3 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult Initial Therapy (age >= 18)

All of:

  • Patient is >= 18 years of age
  • Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
  • Wegovy will be used concomitantly with a behavioral modification program and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Plus any one of:

  • At baseline, patient had a BMI >= 32 kg/m2
  • At baseline, patient had a BMI >= 27 kg/m2 AND at least TWO of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, OSA, CVD, knee osteoarthritis, asthma, COPD, NASH/NAFLD, PCOS, or CAD

Adult Continuation Therapy (age >= 18)

All of:

  • Patient is >= 18 years of age
  • Patient has lost >= 5% of baseline body weight
  • Wegovy will be used concomitantly with a behavioral modification program and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology
  • Patient has completed at least 7 months of initial therapy OR is within initial approval period

Plus any one of:

  • At baseline, patient had a BMI >= 32 kg/m2
  • At baseline, patient had a BMI >= 27 kg/m2 AND at least TWO weight-related comorbidities

Pediatric Initial Therapy (age 12 to <18)

All of:

  • Patient is >= 12 years of age and < 18 years of age
  • Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
  • At baseline, patient had a BMI >= 95th percentile for age and sex
  • Wegovy (injectable only) will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Pediatric Continuation Therapy (age 12 to <18)

All of:

  • Patient is >= 12 years of age and < 18 years of age
  • At baseline, patient had a BMI >= 95th percentile for age and sex
  • Patient has had a reduction in BMI of >= 1% from baseline
  • Wegovy (injectable only) will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology
  • Patient has completed at least 7 months of initial therapy OR is within initial approval period

Plus any one of:

  • Patient is able to tolerate a Wegovy maintenance dose of 1.7 mg or 2.4 mg once weekly (approve for 1 year)
  • Patient has received < 12 consecutive months of Wegovy AND prescriber confirms patient is continuing to titrate to target dose (approve up to 5 months)

Documentation to bring

  • Documentation of baseline BMI (>= 32 kg/m2, OR >= 27 kg/m2 with at least two qualifying comorbidities) prior to any GLP-1 or GLP-1/GIP agonist use
  • Documentation of at least 3-month trial of behavioral modification and dietary restriction
  • For BMI >= 27 pathway: documentation of at least two qualifying weight-related comorbidities
  • For pediatric patients: documentation of baseline BMI >= 95th percentile for age and sex
  • For continuation: documentation of >= 5% baseline body weight loss (adults) or >= 1% BMI reduction from baseline (pediatric)
  • For continuation: prescriber attestation of ability to tolerate maintenance dose or confirmation of ongoing dose titration
  • Prescriber specialty credentials (to confirm not in excluded specialty)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, at least 1% reduction in BMI, Adult: must have lost >= 5% of baseline body weight. Pediatric (12-<18): must have had a reduction in BMI of >= 1% from baseline. Patient must be able to tolerate injectable maintenance dose of 1.7 mg or 2.4 mg once weekly OR oral maintenance dose of 25 mg once daily for 1-year approval; alternatively, if still titrating and <12 consecutive months received, approve for up to 5 months. Baseline BMI eligibility is re-verified at continuation, and staying on a maintenance dose of at least 1.7 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Concomitant use with other FDA-approved weight loss medications (e.g., phentermine, benzphetamine, diethylpropion, phendimetrazine, Contrave, Qsymia, orlistat)
  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists
  • Prescriber who specializes primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Policy note: Annual Review Date listed as 07/17/2025; Last Revised Date 01/15/2026. Wegovy is available as oral or injectable for adult weight loss; injectable only for pediatric weight loss. Baseline BMI refers to baseline prior to any GLP-1 or GLP-1/GIP agonist use. Coverage is generally not available unless the member's plan includes weight loss drug benefits. Initial approval for adults is 7 months; continuation approval is up to 1 year if maintenance dose tolerated, or up to 5 months if still titrating (with sufficient duration to reach 12 consecutive months total).

verified June 10, 2026 · source: Weight-Loss-GlucagonLike-Peptide1-GLP1-Agonists.pdf

Wegovy for Heart Disease Risk Reduction

What Medical Mutual requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Prior Authorization is only available for members with plan benefit coverage of weight loss drugs. Medications for the treatment of weight loss are specifically excluded as a covered benefit for many plans.

What you need to qualify

  • Age 18 and older
  • BMI of 27 or higher
  • 6 months of a documented diet and exercise program
  • Established cardiovascular disease (MI, stroke, and PAD)
  • On guideline-directed medical therapy (optimized pharmacotherapy for established cardiovascular disease)

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in Established CVD with Obesity/Overweight

All of:

  • Patient is >= 18 years of age
  • Patient has a BMI >= 27 kg/m2
  • According to the prescriber, the medication will be used in combination with optimized pharmacotherapy for established cardiovascular disease
  • Medication will be used concomitantly with a behavioral modification program and a reduced-calorie diet

Plus any one of:

  • Patient has had a prior myocardial infarction
  • Patient has had a prior stroke (not including TIA)
  • Patient has a history of symptomatic peripheral arterial disease evidenced by: intermittent claudication with ankle-brachial index < 0.85, OR peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease

Documentation to bring

  • Documentation of BMI >= 27 kg/m2
  • Documentation of qualifying cardiovascular event: prior MI, prior stroke (not TIA), or symptomatic PAD (with ankle-brachial index < 0.85, revascularization, or amputation due to atherosclerotic disease)
  • Prescriber attestation that medication will be used in combination with optimized pharmacotherapy for established cardiovascular disease

Approval and renewal

  • Initial approval: 6 months

Not covered when

  • Transient ischemic attack (TIA) does not qualify as a prior stroke
  • Concomitant use with other FDA-approved weight loss medications
  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists

Policy note: Approval is for 6 months initial duration. No explicit continuation criteria listed for CV risk reduction indication. Wegovy oral or injectable forms are both applicable. The policy does not explicitly state that diabetes is excluded for this indication — no excludes_diabetes flag applied.

verified June 10, 2026 · source: Weight-Loss-GlucagonLike-Peptide1-GLP1-Agonists.pdf

Why Wegovy requests get denied by Medical Mutual

Based on what this policy asks for. Fix these before the first submission.

  1. Your specific plan doesn't include the weight loss benefit. Coverage here is conditional on the benefit design (often an optional employer add-on), so confirm it before submitting.
  2. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  3. BMI not documented in the chart notes (or documented without a baseline weight and date).
  4. Qualifying weight-related condition not documented with its own diagnosis code.
  5. No documented diet and exercise program.
  6. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

Medical Mutual has separate Wegovy policies that don't depend on the weight loss benefit:

Wegovy is also sold directly by Novo Nordisk without insurance through NovoCare.

Frequently asked questions

Does Medical Mutual cover Wegovy?
Medical Mutual covers it only when the plan's benefit includes it on Employer / Commercial Insurance.
What BMI do you need for Wegovy under Medical Mutual?
For weight loss on Employer / Commercial Insurance plans, Medical Mutual requires a BMI of 32 or higher, or 27 or higher with a qualifying weight-related condition.
How long does a Wegovy approval last with Medical Mutual?
Initial approvals last 7 months, and renewals are granted in 12-month periods.
What does Medical Mutual require to renew Wegovy?
At least 5% weight loss from the starting weight, at least 1% reduction in BMI, Adult: must have lost >= 5% of baseline body weight. Pediatric (12-<18): must have had a reduction in BMI of >= 1% from baseline. Patient must be able to tolerate injectable maintenance dose of 1.7 mg or 2.4 mg once weekly OR oral maintenance dose of 25 mg once daily for 1-year approval; alternatively, if still titrating and <12 consecutive months received, approve for up to 5 months. Baseline BMI eligibility is re-verified at continuation, and staying on a maintenance dose of at least 1.7 mg.
What if my plan excludes weight loss medications?
Medical Mutual has separate Wegovy policies for heart disease risk reduction, which are covered on some plan types and don't depend on the weight-loss benefit. Wegovy is also available for cash through NovoCare.
How current is this information?
This page reflects Medical Mutual's written policy as of its current version, last verified against the source document on June 10, 2026.

Other medications under Medical Mutual

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes Medical Mutual's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.